Table 2 Animal study: mice received larval products and glucantime via different routes of administration
No. | Groups name | Sex | Mice groups | Route of administration | Time-points |
|---|---|---|---|---|---|
1 | G1 | M | Saliva-treated | IP | Daily |
2 | G2 | M | Saliva-treated | IP | Weekly |
3 | G3 | M | Saliva-treated | IL | Weekly |
4 | G1 | F | Saliva-treated | IP | Daily |
5 | G2 | F | Saliva-treated | IP | Weekly |
6 | G3 | F | Saliva-treated | IL | Weekly |
7 | G4 | M | Hemolymph-treated | IP | Daily |
8 | G5 | M | Hemolymph-treated | IP | Weekly |
9 | G6 | M | Hemolymph-treated | IL | Weekly |
10 | G4 | F | Hemolymph-treated | IP | Daily |
11 | G5 | F | Hemolymph-treated | IP | Weekly |
12 | G6 | F | Hemolymph-treated | IL | Weekly |
13 | G7 | M | Infected-untreated | IP | Daily |
14 | G7 | F | Infected-untreated | IP | Daily |
15 | G8 | M | Glucantime-treated | IP | Daily |
16 | G8 | F | Glucantime-treated | IP | Daily |